Inflammasome as a New Therapeutic Target for Diabetic Complications

Area of Science:

• Immunology
• Molecular Biology
• Pathology

Background:

• Inflammation is a common factor in diseases like diabetes, aging, and neurodegeneration.
• Inflammasomes, including NLRP3, are key intracellular sensors of infection and damage, initiating inflammatory responses.
• The NLRP3 inflammasome activates caspase-1, leading to the release of inflammatory cytokines IL-1β and IL-18, and pyroptosis.

Purpose of the Study:

• To review the role of inflammasomes, with a focus on NLRP3, in the context of diabetes.
• To provide an overview of inflammatory diseases involving inflammasomes.
• To evaluate and discuss patents related to inflammasomes and diabetes.

Main Methods:

• Literature review of inflammasome function in inflammation and diabetes.
• Analysis of scientific publications and patent databases.
• Discussion of specific patent mechanisms (WO2015003246, US20130273588, WO2012016145, CN104258398).

Main Results:

• Inflammasomes are implicated in the inflammatory processes underlying diabetic complications.
• A limited number of patents specifically address the intersection of inflammasomes and diabetes.
• Several patents demonstrate therapeutic or diagnostic approaches targeting inflammasomes.

Conclusions:

• Understanding inflammasome mechanisms is crucial for developing novel therapeutic strategies for diabetic complications.
• Targeting inflammasomes offers potential for managing inflammatory diseases.
• Continued research and patent analysis are vital for advancing treatments.